United States

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

11:29am EDT
Change (% chg)

3.50kr (+2.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Recipharm Q4 EBITDA 229 mln SEK
Thursday, 23 Feb 2017 01:45am EST 

Recipharm AB : Q4 net sales amounted to sek 1 333 million (863), an increase of 54% . Recipharm ab (publ) says proposed share dividend is sek [1.50] (1.50) per share . Q4 ebitda increased by 108% and amounted to sek 229 million (110) .Recipharm ab (publ) says we are well on track to reach our long-term financial targets and overall objectives.  Full Article

Recipharm places SEK 1,000 mln convertible bonds
Thursday, 29 Sep 2016 12:00pm EDT 

Recipharm Ab (Publ) : Says places SEK 1,000 million senior unsecured convertible bonds .Says the bonds will carry a coupon of 2.75 pct per annum, and have a conversion price set at SEK 181.955.  Full Article

Recipharm H1 EBITDA up 20 pct
Friday, 22 Jul 2016 01:51am EDT 

Recipharm Publ Ab : Jan-Jun net sales amounted to sek 2 208 million (1 742), an increase of 27 % . Jan-Jun ebitda increased by 20 % and amounted to sek 376 million (314) giving an ebitda margin of 17.0 % (18.0) . Says going forward i expect our growth-driving strategies, including executing on further acquisition opportunities, to continue to deliver Further company coverage: [RECIb.ST] (Reporting By Johan Ahlander) ((johan.ahlander@thomsonreuters.com;)).  Full Article

Recipharm creates global CDMO leader through SEK 1.7 bln acquisitions
Monday, 18 Apr 2016 01:10am EDT 

Recipharm publ AB:Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India.Recipharm says signed two separate agreements to acquire Kemwell's pharmaceutical contract development and manufacturing (cdmo) businesses.Recipharm says proposed share issue of approximately sek 850 million with preferential rights for existing shareholders.Recipharm says businesses to be acquired had 2015 preliminary net sales of approximately sek 745 million, corresponding to 22 per cent of Recipharm's 2015 total net sales.Recipharm says acquisitions are expected to be accretive to ebitda margin already from 2016 and are well in line with Recipharm's overall financial objectives.The acquisition price for Kemwell's operations in the US and Sweden amounts to approximately USD 85 million (SEK 693 million) on a cash and debt free basis.Closing of the transaction is expected to take place during the second quarter of 2016.The acquisition price for the operations in India amounts to USD 120 million (SEK 982 million) on a cash and debt free basis.  Full Article

Recipharm publ AB prposes a dividend for FY 2015, sets new objectives
Wednesday, 24 Feb 2016 01:45am EST 

Recipharm publ AB:Proposed share dividend is 1.50 (1.25) crown per share​ for FY 2015.New objectives are to reach sales of at least 8 billion crowns by 2020, to have an EBITDA margin of at least 16 pct and to have a net debt to equity ratio less than 0.8​.Objective that 30-50 pct of profit after tax should be distributed as dividend to shareholders remains unchanged​.  Full Article

Recipharm publ AB to acquire Mitim Srl
Tuesday, 23 Feb 2016 01:00pm EST 

Recipharm publ AB:Recipharm to acquire Italian Mitim Srl for 640 million crowns adding scale and niche technology in injectable beta lactams.The transaction is valued to an Enterprise Value of 68 million euros (640 million crowns) equivalent to about 8 times pro forma 2015 EBITDA.Transaction costs of about 4 million crowns will be charged to Q1 results.  Full Article

Recipharm plans to invest EUR 40 mln over three years in new serialisation processes
Wednesday, 10 Feb 2016 05:00am EST 

Recipharm publ AB:Says plans to invest 40 million euros over the next three years to ensure state-of-the-art solutions for serialisation processes.  Full Article

Recipharm publ AB raises 276 mln crowns in directed issue of 2.25 mln shares
Tuesday, 26 Jan 2016 02:00am EST 

Recipharm publ AB:Resolved to carry out a direct share issue of 2,250,000 Class B shares at subscription price of 122.50 crowns per share.Recipharm publ ab says ‍issue entails a dilution of about 4.7 per cent of capital​.  Full Article

Recipharm gets regulatory approval for acquisition of Nitin Lifesciences
Friday, 15 Jan 2016 05:00am EST 

Recipharm publ AB:Says will acquire a majority stake (74 pct) in Nitin Lifesciences Limited.Indian Foreign Investment and Promotion Board has granted approval for this transaction to take place.Closing is expected to take place by the end of Q1 2016.  Full Article

Recipharm inks agreement with Alcon, acquires facility in France
Monday, 21 Dec 2015 08:30am EST 

Recipharm publ AB:Signs manufacturing agreement with Alcon and acquires facility in France, adding new niche capabilities.Says long term manufacturing agreement will add annual sales in excess of 36 million euros and EBITDA-margin well in line with the Group's average.Says adds a new relationship with Alcon and further strengthens the current relationship with Novartis.Says 100 pct of the shares in Kaysersberg Pharmaceuticals will be acquired for a total consideration of 18 million euros.Says about 260 people currently employed by Kaysersberg Pharmaceuticals will continue their employment under Recipharm ownership.  Full Article

More From Around the Web

BRIEF-Recipharm Q4 EBITDA 229 mln SEK

* Q4 net sales amounted to sek 1 333 million (863), an increase of 54%